Diagnostic value of transvaginal ultrasound combined with serum CA125 and HE4 in differentiating benign and malignant ovarian tumors

Background: This study aimed to evaluate the diagnostic value of transvaginal ultrasound combined with the serum carbohydrate antigen125 (CA125) and Human Epididymis Protein 4 (HE4) in distinguishing benign from malignant ovarian tumors. Methods: The data of 140 patients with ovarian tumors were retrospectively analyzed. According to the histopathological diagnosis divided into benign group (109 cases) and malignant group (31 cases). Clinical data, serum biomarkers and transvaginal ultrasound were collected. Multivariate logistic regression and receiver operating characteristic (ROC) curve were used to analyze the diagnostic value of each parameter. Results: No significant differences in body mass index (BMI) or history of abortion between the two groups (p > 0.05). The proportion of postmenopausal patients was significantly higher in malignant group than benign group (p < 0.05). The pulsatility index (PI) and systolic-to-diastolic ratio (S/D) were significantly lower in the benign group than malignant group (p < 0.05), the resistance index (RI) was lower in the benign group but did not reach statistical significance (p > 0.05). Serum CA125 and HE4 levels were significantly higher in the malignant group than benign group (p < 0.05). Multivariate logistic regression analysis showed that RI, PI, S/D, CA125 and HE4 were independent influencing factors for benign and malignant diagnosis of ovarian tumors (p < 0.05). ROC showed that RI, PI, S/D, CA125 and HE4 had diagnostic value, and the area under the curve (AUC) was 0.588, 0.643, 0.698, 0.735 and 0.711, respectively. The diagnostic accuracy of the above combination was the highest, with an AUC of 0.856. Conclusions: The diagnosis of benign and malignant ovarian tumors by transvaginal ultrasound is limited, and the detection of serum markers is not high. Transvaginal ultrasound combined with CA125 and HE4 can significantly improve the accuracy of diagnosis, and has high clinical application value.

Publication Details

Journal
European Journal of Gynaecological Oncology
Published
2025-01-01
DOI
https://doi.org/10.22514/ejgo.2025.073
Citations
1
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
1.70
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Diagnostic value of transvaginal ultrasound combined with serum CA125 and HE4 in differentiating benign and malignant ovarian tumors

1 citations
European Journal of Gynaecological Oncology
Ovarian cancer diagnosis and treatment
1.70
article

Diagnostic value of transvaginal ultrasound combined with serum CA125 and HE4 in differentiating benign and malignant ovarian tumors

article en
1 citations

Abstract

Background: This study aimed to evaluate the diagnostic value of transvaginal ultrasound combined with the serum carbohydrate antigen125 (CA125) and Human Epididymis Protein 4 (HE4) in distinguishing benign from malignant ovarian tumors. Methods: The data of 140 patients with ovarian tumors were retrospectively analyzed. According to the histopathological diagnosis divided into benign group (109 cases) and malignant group (31 cases). Clinical data, serum biomarkers and transvaginal ultrasound were collected. Multivariate logistic regression and receiver operating characteristic (ROC) curve were used to analyze the diagnostic value of each parameter. Results: No significant differences in body mass index (BMI) or history of abortion between the two groups (p > 0.05). The proportion of postmenopausal patients was significantly higher in malignant group than benign group (p < 0.05). The pulsatility index (PI) and systolic-to-diastolic ratio (S/D) were significantly lower in the benign group than malignant group (p < 0.05), the resistance index (RI) was lower in the benign group but did not reach statistical significance (p > 0.05). Serum CA125 and HE4 levels were significantly higher in the malignant group than benign group (p < 0.05). Multivariate logistic regression analysis showed that RI, PI, S/D, CA125 and HE4 were independent influencing factors for benign and malignant diagnosis of ovarian tumors (p < 0.05). ROC showed that RI, PI, S/D, CA125 and HE4 had diagnostic value, and the area under the curve (AUC) was 0.588, 0.643, 0.698, 0.735 and 0.711, respectively. The diagnostic accuracy of the above combination was the highest, with an AUC of 0.856. Conclusions: The diagnosis of benign and malignant ovarian tumors by transvaginal ultrasound is limited, and the detection of serum markers is not high. Transvaginal ultrasound combined with CA125 and HE4 can significantly improve the accuracy of diagnosis, and has high clinical application value.

European Journal of Gynaecological OncologyVol. 46(5)
Zero hunger, Good health and well-being
Openalex Percentile: Top 17%
Ovarian cancer diagnosis and treatment
1.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.